Panacea Biotec's Q4 financials show promising growth in PAT and Net Sales
Panacea Biotec, a microcap pharmaceutical company, has reported a flat performance for the quarter ending March 2024, with a score of 4 out of 10. However, the company's Profit After Tax has shown consistent growth in the last five quarters and Net Sales have increased by 23.12% YoY. Investors should monitor future performance.
Panacea Biotec, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending March 2024. The company's stock has been given a 'Strong Sell' call by MarketsMOJO.According to the financial report, Panacea Biotec's performance for the quarter has remained flat, with a score of 4 out of 10. This is a decrease from the previous quarter's score of 9. However, there are some positive aspects to the company's financials.
One of the highlights is the Profit After Tax (PAT) for the quarter, which stands at Rs -4.73 crore, the highest in the last five quarters. Moreover, the PAT has shown growth in each of the last five quarters, indicating a positive trend in the near term.
Another positive aspect is the Net Sales for the nine-month period, which has grown by 23.12% Year on Year (YoY) to reach Rs 429.98 crore. The near term trend for sales is also positive.
Panacea Biotec's financial results for the quarter ending March 2024 may not be as strong as expected, but the company's PAT and Net Sales show promising growth. Investors should keep an eye on the company's performance in the coming quarters to make informed decisions.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
